Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

Summary

This study is a prospective, multicenter, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory efficacy of nebulized CSL787 after administrations of single (SAD) ascending doses in healthy subjects and multiple (MAD) ascending doses in subjects with NCFB.

Timeline

Start

2020-12-07

Primary completion

2023-03-12

Completion

2023-03-12

Drugs

Indications